Cells adhere to the extracellular matrix (ECM) via specific receptors, mainly integrins, which subsequently activate signaling pathways that regulate a variety of cellular functions, e.g., motility, proliferation, polarity, differentiation, and survival.^[@ref1],[@ref2]^ In the tumor microenvironment, healthy ECM becomes deregulated, causing changes in both composition and architecture, which cancer cells have been shown to utilize to their advantage.^[@ref3]−[@ref5]^ Interactions with the ECM can promote tumor cell extravasation, metastasis, invasion, and most importantly, survival post-chemotherapeutic intervention via the activation of various pro-survival signaling pathways.^[@ref3],[@ref6]−[@ref10]^ Consequently, researchers have taken two main approaches to mitigating such adhesion-conferred chemoprotection---either via the perturbation of activated pro-survival signaling pathways^[@ref11]−[@ref13]^ or via blocking specific integrin-mediated adhesions in order to prevent the onset of signaling pathway initiation.^[@ref14]−[@ref16]^ A seminal example of the latter approach, which has also been extensively studied in the clinic, is the blocking of the RGD cell binding sequence via an engineered cyclic RGD pentapeptide, cilengitide (Merck KGaA). Cilengitide has been shown to greatly hinder angiogenesis, thereby starving the tumor and improving subsequent treatment efficacy and patient outcome in specific cases.^[@ref16]−[@ref18]^

Despite the exploration of numerous other integrin-targeting strategies (reviewed by Holle et al.)^[@ref19]^ with varied outcomes, none have advanced into clinic practice. The primary obstacle in interpreting the limited data available on adhesion-dependent chemoresistance arises from the enormous molecular complexity of the extracellular environment, thereby making it difficult to identify the specific epitopes that are responsible for protective effects. Moreover, recent studies have shown that adhesion-mediated signaling is affected not only by the chemical nature of the adhesive environment but also by multiple physical features of the matrix, including the spatial patterning of adhesive epitopes available for cell binding, the topography of the substrate, and the rigidity of the matrix.^[@ref20]^

Numerous previous reports have identified specific integrin subtypes that contribute to tumor progression (reviewed by Seguin et al.),^[@ref21]^ including α~v~β~3~'s role in breast tumor metastasis to the bone^[@ref22]^ and α~5~β~1~'s role in breast cancer cell invasiveness.^[@ref23]^ While various integrins shown to affect chemosurvival have been the target of therapeutic interventions, a direct comparison of different integrin subtypes in a highly controlled system has not yet been made. Fibronectin-binding integrin subtypes α~v~β~3~ and α~5~β~1~ exhibit individual roles for various cellular processes including force sensing, mediating structural adaptation to forces, focal adhesion formation, and migration.^[@ref24]−[@ref27]^ Most importantly, they have also been shown to regulate chemoresistance in a variety of cancer cells,^[@ref9]^ which leads us to believe that they could be sensitive to alterations in matrix properties.

When studying cell--ligand interactions, it would be prudent to consider the nanoscale spacing between ligands that are presented to cells. Previous work has shown that cells can indeed sense and differentially respond to nanometer-scale alterations in ligand spacing, affecting their migration, morphology, focal adhesion assembly, cell adhesion, and traction force generation.^[@ref28]−[@ref32]^ The spatial organization of available ligand binding partners has been shown to mediate ligand clustering, thereby affecting force-mediated contractility of the cell via "molecular clutches" between integrins and the ECM.^[@ref31],[@ref33],[@ref34]^ Most important to this study, nanoscale ligand spacing has been shown to affect melanoma cancer cell behavior and plasticity,^[@ref35],[@ref36]^ yet the degree to which nanoscale ligand spacing affects chemosurvival in cancer cells is still unknown.

While the exact distribution of ligands in physiological tissues is difficult to discern due to limitations in the resolution and accessibility of current imaging techniques, researchers have been able to shed some light on the range of physiologically relevant ligand spacing of proteins and focal complexes within cells using approaches such as immunogold labeling,^[@ref37]^ crystallography,^[@ref38],[@ref39]^ and advanced imaging techniques.^[@ref40],[@ref41]^ For instance, collagen bundles exhibit a periodic structure occurring around 70 nm which is believed to be the length scale at which cells attach to the protein,^[@ref42]^ while periodic binding domains in fibronectin have been identified to be as close as 42 nm.^[@ref37]^ Furthermore, heterotypic protein assemblies have been shown to alter binding site spacing, decreasing the distance between sites by up to ∼20% from that of homotypic fibrils.^[@ref37]^ While *in vivo* measurements are still lacking, these investigations are complicated by the fact that cancer cells can actively reorganize the ECM, likely altering the density of ligand binding sites dynamically.^[@ref43],[@ref44]^ Taken together, we aim to better understand the interplay of integrin subtypes and nanoscale spacing of ligands in the chemosurvival of breast cancer cells by utilizing a highly defined platform.

To achieve this, we investigated two integrin subtypes that are known to be expressed in solid tumors, α~v~β~3~ and α~5~β~1~.^[@ref21],[@ref45]^ These integrin subtypes recognize the RGD-binding sequence found in proteins commonly present or overexpressed in the tumor microenvironment, including fibronectin, osteopontin, and/or vitronectin. In order to study their individual roles, highly specific integrin subtype peptidomimetics were synthesized.^[@ref46]^ We first plated human metastatic MDA-MB-231 breast cancer cells on human fibronectin (Fn), which contains binding sites for both α~v~β~3~ and α~5~β~1~ integrin subtypes, and examined cell morphology with or without the addition of subtype-specific peptidomimetics capable of blocking integrins α~v~β~3~ or α~5~β~1~ (experimental design outlined in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A). When blocking α~v~β~3~ (thereby engaging α~5~β~1~), cells maintain a similar spread area compared to Fn alone, and become slightly more rounded ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B, top row; [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C). When blocking α~5~β~1~, thereby engaging α~v~β~3~, cells become significantly smaller and rounder ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B, top row; [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C,D), which is consistent with cells plated on vitronectin (Vn), where α~v~β~3~ is the major binding integrin ([Figure S1A--C](http://pubs.acs.org/doi/suppl/10.1021/acs.nanolett.9b04607/suppl_file/nl9b04607_si_001.pdf)).

![Integrin-specific engagement on fibronectin alters cellular and focal adhesion morphology. (A) MDA-MB-231s were plated on immobilized fibronectin and treated with blocking peptidomimetics as follows: no blocking peptidomimetics engages both integrins \[left\]; blocking of α~v~β~3~ (blue \^) results in engagement of α~5~β~1~ (purple) \[middle\]; and blocking of α~5~β~1~ (purple \^) results in engagement of α~v~β~3~ (blue) \[right\]. (B) Cells were stained for actin (red), paxillin (green), and nucleus (blue) for (1) both α~5~β~1~ and α~v~β~3~ engagement (left column), (2) α~5~β~1~ engagement (middle column), and (3) α~v~β~3~ engagement (right column), with or without drug treatment (no drug, top row; +5-FU, middle row; +paclitaxel, bottom row). Insets show zoomed in focal adhesions. Scale bar: 50 μm. All images without a scale bar have the same scaling as the bottom right image. Cell morphology in terms of (C) cell area (in μm^2^) and (D) form factor was quantified for all conditions, i.e., α~5~β~1~ and α~v~β~3~ engagement ("Both", green bars), α~5~β~1~ engagement (purple bars), and α~v~β~3~ engagement (blue bars), with or without drug treatment as indicated (no drug, no outline; +5-FU, black outline; +paclitaxel, gray outline). Focal adhesion (FA) morphology in terms of (E) FA area (in μm^2^) and (F) major axis length (in μm) was quantified for all conditions and graphed as in parts C and D. Data are mean ±95% CI from *n*~cells~ \> 186 and *n*~FAs~ \> 771. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001 by one-way ANOVA. All significance comparisons are listed in [Table S1](http://pubs.acs.org/doi/suppl/10.1021/acs.nanolett.9b04607/suppl_file/nl9b04607_si_001.pdf).](nl9b04607_0001){#fig1}

In order to assess effects of chemotherapeutic drugs, we employed two commonly used compounds from which cells have been reported to have developed chemoresistance: 5-fluorouracil (5-FU), which blocks DNA replication, and paclitaxel (also commonly referred to as Taxol), which disrupts microtubule breakdown.^[@ref47]^ When treated with 5-FU, cells on Fn become more elongated in all conditions ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B, middle row; [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}D), while paclitaxel treatment causes cells to become very large and rounded ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B, bottom row; [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C,D), highlighting that the different mechanisms of action of the two drugs can affect subsequent cell morphology in surviving cells. The fact that these responses are also dependent upon specific ligand interactions underscores the synergy between these two biochemical pathways ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B).

Focal adhesion (FA) formation and the subsequent activation of downstream signaling pathways have been shown to be important indicators of cancer cell invasiveness.^[@ref48]^ As FAs play a major role in substrate sensing and mechanotransduction,^[@ref49]^ previous studies have linked alterations in FA formation to various substrate properties, e.g., stiffness, ligand type, topography, dimensionality, etc.^[@ref50],[@ref51]^ Our results show that FA formation is affected not only by integrin subtype engagement but also by drug treatment. First, we observe that cells engaging only α~v~β~3~ form small, short adhesions ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B, top row; [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}E,F; [Figure S1A,D,E](http://pubs.acs.org/doi/suppl/10.1021/acs.nanolett.9b04607/suppl_file/nl9b04607_si_001.pdf)). While drug treatment does not greatly affect FA formation on Fn alone, engagement of α~5~β~1~ greatly hinders FA clustering in drug-treated cells ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B, middle and bottom rows; [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}E,F). Conversely, drug treatment in conjunction with α~v~β~3~ engagement results in FA size enhancement, with paclitaxel inducing the largest FAs ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B, middle and bottom rows; [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}E,F). Overall, both cell and FA morphology were most notably affected by α~v~β~3~ engagement, further underscoring the role this integrin subtype plays in breast cancer cell behavior.

While native proteins are an important substrate for studying integrin subtype-specific effects, uncontrolled parameters are inherent to such systems (e.g., ligand spacing, the presence of other integrin subtype binding sites, etc.) that can obscure the role of primary mediators of cell-ECM behavior. To better isolate these variables, we synthesized highly ordered gold nanoparticle (AuNP) arrays via the previously described block copolymer micelle nanolithography (BCMN) technique^[@ref52]^ in order to control both ligand spacing/density and type. AuNP arrays with interparticle spacings of 35, 50, and 70 nm were produced and characterized via SEM ([Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acs.nanolett.9b04607/suppl_file/nl9b04607_si_001.pdf)). Such biologically relevant spacings were chosen based on previous reports of protein binding site organization, conformation of proteins, and *in vitro* experiments showing restricted integrin clustering on substrates with ligand spacing greater than ∼73 nm.^[@ref20]^ Thiolated versions of the aforementioned integrin-subtype-specific peptidomimetics were synthesized that could specifically attach to the AuNPs,^[@ref46]^ thereby resulting in a highly controlled and highly defined nanoscale substrate (schematic of experimental outline in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A).

![Integrin subtype-specific engagement at defined nanospacing alters cellular and focal adhesion morphology. (A) MDA-MB-231s were plated on integrin-specific peptidomimetics, i.e., α~5~β~1~ (purple) or α~v~β~3~ (blue), immobilized on AuNPs with interspacings of 35, 50, or 70 nm. (B) Cells were stained for actin (red), paxillin (green), and nucleus (blue) on samples with AuNP spacing of (i) 35 nm, (ii) 50 nm, or (iii) 70 nm functionalized with either α~5~β~1~ (top of each set) or α~v~β~3~ (bottom of each set), with or without drug treatment (no drug, left column; +5-FU, middle column; +paclitaxel, right column). Insets show zoomed in focal adhesions. Scale bar: 50 μm. (C) Cell morphology in terms of area (C, μm^2^) and form factor (D) was quantified for all conditions, i.e., α~5~β~1~ (purple) or α~v~β~3~ (blue) engagement at 35, 50, or 70 nm (where decreasing opacity corresponds with increasing spacing), with or without drug treatment (no drug, no outlines; +5-FU, black outline; +paclitaxel, gray outline). Focal adhesion (FA) morphology in terms of area (E, μm^2^) and major axis length (F, μm) was quantified and graphed for all conditions as in parts C and D. Data are mean ±95% CI from *n*~cells~ \> 71 and *n*~FAs~ \> 376. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001 by one-way ANOVA. All significance comparisons are listed in [Table S2](http://pubs.acs.org/doi/suppl/10.1021/acs.nanolett.9b04607/suppl_file/nl9b04607_si_001.pdf).](nl9b04607_0002){#fig2}

In general, cells were smaller on AuNP surfaces compared to Fn-coated substrates ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C vs [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C), likely due to differences in binding site availability and organization, which would be enhanced on Fn-coated substrates. Compared to cells on α~5~β~1~-coated surfaces, cells on α~v~β~3~-coated surfaces were much larger and more fully spread on 70 nm spacing ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B--D). Overall, both integrin subtypes were affected by spacing, albeit at different length scales, as previously reported for various other cell types.^[@ref29],[@ref53]^ On α~5~β~1~, cell spread area and form factor were significantly higher on 35 nm compared to 50 or 70 nm, while on α~v~β~3~, cells on 50 nm spacing elicited a significantly different morphology compared to 70 nm ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C,D). Drug treatment was found to enhance this spacing-sensitive response. Paclitaxel-treated cells plated on α~v~β~3~ exhibited significant differences in cell area between 35 and 50 or 70 nm ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C). When comparing the effects of specific spacings on the two integrin subtypes, larger nanoscale ligand spacing resulted in the greatest changes between the two, regardless of condition, while cells on 35 nm were more highly affected by drug treatment on α~v~β~3~ vs α~5~β~1~ ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C,D). Additionally, cells plated on α~v~β~3~-coated surfaces were more affected by drug treatment than those on α~5~β~1~, exhibiting a decrease in cell area with 5-FU treatment at 35 and 50 nm, and an increase at 70 nm. The exact opposite of this pattern was observed in response to paclitaxel treatment, suggesting that the nanoscale environment can impact the morphological response to chemo drugs in a pathway-specific fashion ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B,C).

Mirroring morphological observations, FA formation in cells on α~v~β~3~-coated surfaces was more affected by drug treatment than FAs in cells on α~5~β~1~-coated surfaces ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B,E,F). FA area, but not necessarily length, on α~5~β~1~ is generally enhanced on larger spacing vs smaller spacing ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B,E,F), as has been previously reported in osteosarcoma cells.^[@ref53]^ Interestingly, on α~v~β~3~-coated surfaces, FA area and length were particularly sensitive to paclitaxel treatment. Compared to control groups, FA area and length in paclitaxel-treated cells decreased on 35 nm, remained unchanged on 50 nm, and increased on 70 nm ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}E,F). In general, drug treatment significantly altered FA characteristics in almost all conditions. This shows that, while neither drug specifically targets focal contacts, global changes in cellular organization in response to chemo drugs are connected to dynamic alterations of focal adhesion presentation, and that these alterations are modulated by nanoscale ECM organization. Taken together, cellular and FA morphology data indicate that cancer cells are sensitive to both ligand type and nanoscale ligand spacing, and that this sensitivity may play a role in ECM-modulated chemoresistance.

Altered cell motility usually accompanies the transformation of a cancer cell to a metastatic or chemoresistant phenotype.^[@ref54],[@ref55]^ Additionally, subtype-specific integrin expression and abundance have been shown to be altered in cancer progression.^[@ref56]^ Therefore, we analyzed cancer cell migration as a function of integrin engagement, dimensionality, and drug treatment ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). We found that cells plated on Fn slowed in response to either drug treatment, but most significantly with paclitaxel. Cells engaging only α~5~β~1~ on Fn behaved similarly to cells in which both integrins could be bound (i.e., on Fn alone), mirroring cell morphology patterns ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). When engaging only α~v~β~3~ on Fn, cell speed decreased, a pattern which was enhanced with paclitaxel treatment ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). On AuNP arrays, cells on α~v~β~3~-coated surfaces were slower, in general, than cells on α~5~β~1~-coated surfaces ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). Interestingly, cells of all conditions were slower on 50 nm spacing than on 35 or 70 nm spacing, where they exhibited similar speeds. While both drug treatments resulted in decreased cell speed on α~v~β~3~, only paclitaxel reduced speed on α~5~β~1~. Lastly, cell trajectories on Fn or AuNPs treated with paclitaxel were examined compared to controls due to the fact that paclitaxel treatment hindered cell movement in nearly all conditions ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C). Cells on 70 nm spaced AuNPs were more exploratory than those on narrower spacings, which was most pronounced on α~v~β~3~-coated surfaces. This was echoed on fibronectin-coated substrates, where paclitaxel-treated cells engaging α~v~β~3~ were also more exploratory than those engaging α~5~β~1~ ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C). Previous studies have found differing roles for integrin subtypes in migration; e.g., β~1~ promotes a more random migration pattern compared to β~3~, which is ultimately regulated through Rho GTPases.^[@ref57]^ These data suggest that this is not only a function of integrin subtype but also the nanoscale presentation of extracellular ligands in combination with drug treatment.

![Integrin subtype-specific and nanospacing-specific cell motility. (A) Cell motility (cell speed in μm/min) for integrin subtype-specific engagement on fibronectin using blocking peptidomimetics vs ligand type (both α~5~β~1~ and α~v~β~3~ engagement, green; α~5~β~1~ engagement, purple; α~v~β~3~ engagement, blue) and drug treatment (no drug, no outline; +5-FU, black outline; +paclitaxel, gray outline). (B) Cell motility for integrin subtype-specific engagement on peptidomimetics immobilized on AuNPs with interspacings of 35, 50, or 70 nm. Data plotted as in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}, i.e., α~5~β~1~ (purple) or α~v~β~3~ (blue) engagement at 35, 50, or 70 nm (where decreasing opacity corresponds with increasing spacing), with or without drug treatment (no drug, no outlines; +5-FU, black outline; +paclitaxel, gray outline). (C) Representative cell trajectories depicted as roseplots from the first 17 h of the experiment of cells engaging α~5~β~1~ (two left columns) or α~v~β~3~ (two right columns) without drug treatment or with paclitaxel treatment (left and right column, respectively, of each set) for cells plated on fibronectin (top row) or on AuNPs with interspacing of 35 nm (second row), 50 nm (third row), and 70 nm (last row). *n*~Fn,tracks~ \> 287; *n*~AuNP,tracks~ \> 93; *r* = 2. Data are mean ± SEM. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001 by one-way ANOVA.](nl9b04607_0003){#fig3}

While cell metrics like morphology, focal adhesion formation, and motility show that both integrin subtype and ligand nanospacing are important mediators of cancer cell behavior, how these two parameters influence cell survival has important implications in therapeutic applications and drug screening. Therefore, cell survival was assessed after 48 h of drug treatment based on integrin subtype on both Fn and AuNP arrays, with either 5-FU or paclitaxel treatment ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). When treated with either drug, cells on Fn alone exhibited similar survival as when only α~5~β~1~ was engaged on Fn ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). However, when only α~v~β~3~ was engaged on Fn, survival was enhanced by up to ∼20% with 5-FU treatment and ∼10% with paclitaxel ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A).

![Chemosurvival is dependent on integrin subtypes and nanoscale dimensionality. (A) Percent survival of cells treated with 5-FU (black outline) or paclitaxel (gray outline) plated on fibronectin with integrin-specific engagement as indicated (both, i.e., α~5~β~1~ and α~v~β~3~, green; α~5~β~1~, purple; α~v~β~3~, blue). (B) Percent survival of cells treated with 5-FU (black outline) or paclitaxel (denoted as "P" on the *x*-axis, gray outline) on AuNPs functionalized with integrin-subtype-specific peptidomimetics (α~5~β~1~ engagement, purple; α~v~β~3~ engagement, blue) at interspacing of 35, 50, or 70 nm (where decreasing opacity corresponds with increasing spacing). For samples in part A, *n* = 8; part B, *n* = 7. Data are mean ± SEM. \*\**p* \< 0.01, \*\*\**p* \< 0.001 by one-way ANOVA for part A and \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001 by two-way ANOVA for part B.](nl9b04607_0004){#fig4}

The similarities found between the engagement of both integrin subtypes and the α~5~β~1~-only engagement can be explained by the fact that MDA-MB-231 cells express β~1~ more readily than α~v~,^[@ref58]^ indicating that α~5~β~1~ is likely the dominant ligand partner for MDA-MB-231 cells on Fn. Although, expression alone does not necessarily indicate functional output, as distinct but complementary roles for these two integrin subtypes in regulating contractility and adhesion strength have been shown in fibroblasts.^[@ref24],[@ref59]^ Furthermore, it is well-known that α~v~β~3~ promotes breast cancer metastasis to the bone niche,^[@ref22]^ which could explain the enhancement in chemosurvival we observe when engaging only this integrin subtype.

Next, we looked at drug responsiveness as a function of ligand spacing and integrin subtype using the AuNP arrays. Importantly, we observed that cancer cell survival in response to chemotherapeutic treatment is highly dependent on nanoscale ligand spacing, an observation not yet reported in the literature. We demonstrated differences in survival not only between the two integrin subtypes, but also between drug type and ligand spacing. When cancer cells engage α~5~β~1~ integrins, higher spacing improves survival with both 5-FU and paclitaxel treatment, but the length scale at which this occurs is drug-dependent; i.e., 50 nm enhances survival with 5-FU, while larger spacing is required for paclitaxel ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B). On α~v~β~3~, we observe the same trend with paclitaxel treatment, but a different trend in how spacing affects cell survival with 5-FU treatment, namely, that 50 nm spacing enhances chemosurvival ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B).

Optimal ligand spacing for cell spreading has previously been reported in various cell lines to be between ∼58 and 73 nm.^[@ref28]^ Indeed, we observed that survival was low on 35 nm substrates vs larger spacing for all conditions, indicating that integrin-mediated pro-survival signaling could be hindered at such length scales. Supporting this, we found impaired focal adhesion formation at 35 nm, as has been previously demonstrated in melanoma cells. In that investigation, the authors linked this impaired FA formation to the restricted size of focal adhesion proteins, i.e., talin at ∼60 nm, and the restricted lateral motion of integrins during clustering.^[@ref35]^

Most notably, we find that, by altering only nanoscale ligand spacing, we were able to increase cancer cell chemosurvival by over 40% ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B, α~5~β~1~/paclitaxel/50 vs 70 nm), a surprisingly large magnitude given the small change in ECM conditions. These data suggest that even nanoscale alterations in ligand presentation can significantly alter cancer cell survival in response to chemotherapeutic treatment, and that these alterations are affected by not only the ligand type but also the type of drug utilized in treatment. The observed differential responses in chemosurvival among the different conditions likely stem from integrin subtype-specific activation of pro-survival signaling pathways, e.g., FAK, PI3K, or Akt,^[@ref60],[@ref61]^ which would be worthwhile to explore in future studies.

Although this study examined nanoscale ligand spacing on rigid glass substrates, ECM stiffness has been shown to be an important mediator in mechanotransduction. Moreover, it has been shown that matrix stiffness affects chemoresistance through such mechanisms as cellular stiffening, focal adhesion-driven signaling, or promoting the epithelial-to-mesenchymal transition.^[@ref10],[@ref62],[@ref63]^ Intriguingly, the α~5~β~1~ and α~v~β~3~ integrin subtypes have been shown to distinctly modulate force transmission at the cell--ECM interface^[@ref64]^ via the activation of unique signaling pathways.^[@ref65]−[@ref67]^ Thus, future studies will focus on untangling the complex interplay of matrix stiffness and ligand presentation in regulating chemoresistance. This can be realized by utilizing the well-established technique of transfer nanolithography, in which AuNP arrays can be transferred onto soft polymeric substrates.^[@ref68]^ Taken together, these data call not only for a better understanding of the intricate tumor microenvironment but also for more faithful ECM mimics for cancer drug screening.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acs.nanolett.9b04607](https://pubs.acs.org/doi/10.1021/acs.nanolett.9b04607?goto=supporting-info).Materials and methods section, description of supporting experiments, tables of signficance, and additional data and figures including cells plated on vitronectin, integrin subtype immunostaining, SEM of samples produced by block copolymer micelle nanolithography, cellular proliferation, drug dose curves, and low magnification images of cells ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.nanolett.9b04607/suppl_file/nl9b04607_si_001.pdf))
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